<?xml version='1.0' encoding='utf-8'?>
<document id="29330218"><sentence text="A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects." /><sentence text="Understanding liver exposure of hepatic transporter substrates in clinical studies is often critical, as it typically governs pharmacodynamics, drug-drug interactions, and toxicity for certain drugs" /><sentence text=" However, this is a challenging task since there is currently no easy method to directly measure drug concentration in the human liver" /><sentence text=" Using bosentan as an example, we demonstrate a new approach to estimate liver exposure based on observed systemic pharmacokinetics from clinical studies using physiologically based pharmacokinetic modeling"><entity charOffset="7-15" id="DDI-PubMed.29330218.s4.e0" text="bosentan" /></sentence><sentence text=" The prediction was verified to be both accurate and precise using sensitivity analysis" /><sentence text=" For bosentan, the predicted pseudo steady-state unbound liver-to-unbound systemic plasma concentration ratio was 34"><entity charOffset="5-13" id="DDI-PubMed.29330218.s6.e0" text="bosentan" /></sentence><sentence text="9 (95% confidence interval: 4" /><sentence text="2, 50)" /><sentence text=" Drug-drug interaction (i" /><sentence text="e" /><sentence text=", CYP3A and CYP2B6 induction) and inhibition of hepatic transporters (i" /><sentence text="e" /><sentence text=", bile salt export pump, multidrug resistance-associated proteins, and sodium-taurocholate cotransporting polypeptide) were predicted based on the estimated unbound liver tissue or plasma concentrations"><entity charOffset="71-90" id="DDI-PubMed.29330218.s13.e0" text="sodium-taurocholate" /></sentence><sentence text=" With further validation and refinement, we conclude that this approach may serve to predict human liver exposure and complement other methods involving tissue biopsy and imaging" /><sentence text="" /></document>